Abstract：
OBJECTIVE: To evaluate the efficiency of pemetrexed cisplatin in comparison with gemcitabine cisplatin and to validate the EORTC (European Organisation for Research and Treatment of Cancer) prognostic score in combination chemotherapy treatment for malignant pleural mesothelioma.
METHODS: An observational study. Place and Duration of the Study: Department of Oncology, Dicle University Hospital, Diyarbakir, Turkiye, from October 2000 to November 2017.
METHODS: Malignant pleural mesothelioma (MPM) patients with EORTC score 0- were recruited. Factors affecting the prognosis of the disease and the effectiveness of first-line treatment were retrospectively analysed. EORTC prognostic score was calculated with a cut-off and survival analyses were used by the Kaplan-Meier method. Log-rank and univariable Cox regression tests were used to search for prognostic factors\' impact on survival.
RESULTS: Patients who received gemcitabine cisplatin treatment had a median progression-free survival (PFS) of 9 months, while those who received pemetrexed cisplatin therapy had a median PFS of 7 months. Median overall survival (OS) was 17 months in the gemcitabine cisplatin group and 18 months in the pemetrexed cisplatin group (p = 0.051). When the low-risk group was compared with the high-risk group, the median OS was found to be statistically significant (p = 0.009).
CONCLUSIONS: The EORTC prognostic score, which is used for prognostic prediction in the period when pemetrexed is not utilised in the treatment of MPM, accurately predicts prognosis subsequent to the administration of pemetrexed in treatment. In the context of first-line treatment, cisplatin in combination with gemcitabine and cisplatin in combination with pemetrexed demonstrated comparable efficacy with respect to both overall survival and progression-free survival.
BACKGROUND: Chemotherapy, Mesothelioma, Prognosis, Gemcitabine, Progression-free survival.
METHODS: An observational study. Place and Duration of the Study: Department of Oncology, Dicle University Hospital, Diyarbakir, Turkiye, from October 2000 to November 2017.
METHODS: Malignant pleural mesothelioma (MPM) patients with EORTC score 0- were recruited. Factors affecting the prognosis of the disease and the effectiveness of first-line treatment were retrospectively analysed. EORTC prognostic score was calculated with a cut-off and survival analyses were used by the Kaplan-Meier method. Log-rank and univariable Cox regression tests were used to search for prognostic factors\' impact on survival.
RESULTS: Patients who received gemcitabine cisplatin treatment had a median progression-free survival (PFS) of 9 months, while those who received pemetrexed cisplatin therapy had a median PFS of 7 months. Median overall survival (OS) was 17 months in the gemcitabine cisplatin group and 18 months in the pemetrexed cisplatin group (p = 0.051). When the low-risk group was compared with the high-risk group, the median OS was found to be statistically significant (p = 0.009).
CONCLUSIONS: The EORTC prognostic score, which is used for prognostic prediction in the period when pemetrexed is not utilised in the treatment of MPM, accurately predicts prognosis subsequent to the administration of pemetrexed in treatment. In the context of first-line treatment, cisplatin in combination with gemcitabine and cisplatin in combination with pemetrexed demonstrated comparable efficacy with respect to both overall survival and progression-free survival.
BACKGROUND: Chemotherapy, Mesothelioma, Prognosis, Gemcitabine, Progression-free survival.
摘要：
目的：评估培美曲塞顺铂与吉西他滨顺铂的疗效，并验证EORTC（欧洲癌症研究与治疗组织）在恶性胸膜间皮瘤联合化疗治疗中的预后评分。
方法：观察性研究。研究的地点和持续时间：肿瘤科，Dicle大学医院,迪亚巴克尔,Turkiye,从2000年10月到2017年11月。
方法：招募EORTC评分为0-的恶性胸膜间皮瘤（MPM）患者。回顾性分析影响疾病预后的因素和一线治疗的有效性。用截止值计算EORTC预后评分，并通过Kaplan-Meier方法进行生存分析。使用Log-rank和单变量Cox回归检验来搜索预后因素对生存的影响。
结果：接受吉西他滨顺铂治疗的患者中位无进展生存期（PFS）为9个月，而接受培美曲塞顺铂治疗的患者的中位PFS为7个月.吉西他滨顺铂组的中位总生存期（OS）为17个月，培美曲塞顺铂组的中位总生存期为18个月（p=0.051）。当将低风险组与高风险组进行比较时，中位OS差异有统计学意义(p=0.009).
结论：EORTC预后评分，用于在不使用培美曲塞治疗MPM期间的预后预测，准确预测培美曲塞治疗后的预后。在一线治疗的背景下，顺铂联合吉西他滨和顺铂联合培美曲塞在总生存期和无进展生存期方面显示出相当的疗效.
背景：化疗，间皮瘤,预后,吉西他滨,无进展生存。
方法：观察性研究。研究的地点和持续时间：肿瘤科，Dicle大学医院,迪亚巴克尔,Turkiye,从2000年10月到2017年11月。
方法：招募EORTC评分为0-的恶性胸膜间皮瘤（MPM）患者。回顾性分析影响疾病预后的因素和一线治疗的有效性。用截止值计算EORTC预后评分，并通过Kaplan-Meier方法进行生存分析。使用Log-rank和单变量Cox回归检验来搜索预后因素对生存的影响。
结果：接受吉西他滨顺铂治疗的患者中位无进展生存期（PFS）为9个月，而接受培美曲塞顺铂治疗的患者的中位PFS为7个月.吉西他滨顺铂组的中位总生存期（OS）为17个月，培美曲塞顺铂组的中位总生存期为18个月（p=0.051）。当将低风险组与高风险组进行比较时，中位OS差异有统计学意义(p=0.009).
结论：EORTC预后评分，用于在不使用培美曲塞治疗MPM期间的预后预测，准确预测培美曲塞治疗后的预后。在一线治疗的背景下，顺铂联合吉西他滨和顺铂联合培美曲塞在总生存期和无进展生存期方面显示出相当的疗效.
背景：化疗，间皮瘤,预后,吉西他滨,无进展生存。
